Heparin-induced thrombocytopenia and thrombosis syndrome:: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin

被引:31
作者
Keng, TB [1 ]
Chong, BH [1 ]
机构
[1] Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia
关键词
danaparoid; r-Hirudin; heparin; thrombocytopenia; HITTS;
D O I
10.1046/j.1365-2141.2001.02943.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) is an immune-mediated drug reaction that occurs 5-14 d after initiation of heparin therapy and is a potentially life-threatening thrombotic complication. The antibody-heparin-PF4 complexes cause platelet activation and generation of platelet microparticles. The need for anticoagulant treatment in asymptomatic thrombocytopenia. is uncertain. However, treatment is warranted In HITTS, as illustrated in the case reported here. Danaparoid, r-Hirudin and argatroban are effective drugs. Danaparoid has a 10-50% in vitro cross-reactivity rate with the HIT antibodies, but has been proven to be clinically efficacious even in these cases, Here, we report a case of in vivo cross-reactivity with danaparoid, the patient showed an excellent recovery with r-Hirudin.
引用
收藏
页码:394 / 396
页数:3
相关论文
共 36 条
  • [21] White-clot-syndrome in heparin-induced thrombocytopenia type II with cross reactivity to danaparoid [White-clot-Syndrom bei Heparin-induzierter Thrombozytopenie Typ II mit Kreuzreaktion gegen Danaparoid-Na (Orgaran)]
    Pfeiffer G.
    Eberhardt J.
    Hamann R.
    Gefässchirurgie, 2000, 5 (2) : 125 - 129
  • [22] Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia
    Salmi, L.
    Elalamy, I.
    Leroy-Matheron, C.
    Houel, R.
    Thebert, D.
    Duvaldestin, P.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2006, 25 (11-12): : 1144 - 1148
  • [23] Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome
    Lewis, BE
    Iaffaldano, R
    McKiernan, TL
    Rao, LM
    Donkin, J
    Wallenga, JM
    CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1996, 38 (02): : 206 - 209
  • [25] High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerations
    Hellwig, Thaddaus R.
    Peitz, Gregory J.
    Gulseth, Michael P.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (06) : 490 - 495
  • [26] Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia
    Harenberg, J
    Huhle, G
    Wang, LC
    Hoffmann, U
    Song, XH
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (02) : 360 - 363
  • [27] Thromboembolic prophylaxis with danaparoid (Orgaran®) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease
    Macchi, L
    Sarfati, R
    Guicheteau, H
    Chamlian, V
    Pourrat, O
    Gruel, Y
    Magnin, G
    Brizard, A
    Boinot, C
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2000, 6 (04) : 187 - 189
  • [28] Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: A registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease - The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee
    Ohman, EM
    Granger, CB
    Rice, L
    Abrams, CS
    Becker, RC
    Berger, PB
    Kleiman, NS
    Moliterno, D
    Moll, S
    Rodgers, JE
    Steinhubl, SS
    Tapson, VF
    Sinnaeve, P
    Anstrom, KJ
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2005, 19 (01) : 11 - 19
  • [29] Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular DiseaseThe Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee
    E. Magnus Ohman
    Christopher B. Granger
    Lawrence Rice
    Charles S. Abrams
    Richard C. Becker
    Peter B. Berger
    Neal S. Kleiman
    David Moliterno
    Stephan Moll
    Jo E. Rodgers
    Stephen S. Steinhubl
    Victor F. Tapson
    Peter Sinnaeve
    Kevin J. Anstrom
    Journal of Thrombosis and Thrombolysis, 2005, 19 : 11 - 19
  • [30] Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis - A clinical outcome study
    Chong, BH
    Gallus, AS
    Cade, JF
    Magnani, H
    Manoharan, A
    Oldmeadow, M
    Arthur, C
    Rickard, K
    Gallo, J
    Lloyd, J
    Seshadri, P
    Chesterman, CN
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (05) : 1170 - 1175